Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection, solution - excipient ingredients: trometamol; dilute hydrochloric acid; sodium calcium edetate; water for injections; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; dilute hydrochloric acid; water for injections; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection - excipient ingredients: dilute hydrochloric acid; water for injections; trometamol; sodium calcium edetate; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 311.7 mg/ml - injection - excipient ingredients: trometamol; water for injections; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; dilute hydrochloric acid; trometamol; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - iodine 240 mg in 1 ml - ultravist® injection is an iodinated contrast agent indicated for: *for information on the concentrations and doses for the pediatric population [see dosage and administration (2.3) and use in specific populations (8.4)]. risk summary there are no data on ultravist injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to 0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data). . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general p

Združene države Amerike - angleščina - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - ultravist® injection is an iodinated contrast agent indicated in adults pediatric patients for use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this imaging bulk package. risk summary there are no data on ultravist injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to 0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data). . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of

Izrael - angleščina - Ministry of Health

bayer israel ltd - iopromide - solution for injection - iopromide 623.4 mg / 1 ml - iopromide - iopromide - contrast enhancement in computerized tomography (ct) , digital subtraction angiography (dsa), intravenous urography, arteriography ,phlebography of the extremities, venography, visualization of body cavities (e.g. arthrography, hysterosalpingography,fistulography) with the exception of myelography, ventriculography, cisternography.

Izrael - angleščina - Ministry of Health

bayer israel ltd - iopromide - solution for injection - iopromide 768.86 mg/ml - iopromide - iopromide - contrast enhancement in computerized tomography (ct) , digital subtraction angiography (dsa), intravenous urography, arteriography and especially angiocardiography, visualization of body cavities (e.g. arthrography, fistulography) with the exception of myelography, ventriculography, cisternography.

Singapur - angleščina - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - iopromide eqv iodine - injection - 623.40 mg - iopromide eqv iodine 300 mg/ml